According to a recent joint announcement by the U.S. Food and Drug Administration (FDA) and the National Institute on Drug Abuse (NIH), the seventh wave of data files for the Population Assessment of Tobacco and Health (PATH) study's biomarker data (BRUF) has been released. This marks the first release of biomarker data collected between January 2022 and April 2023.
According to the official website of the FDA, the PATH (Population Assessment of Tobacco and Health) study is a large-scale, long-term research project on tobacco use and health in the United States. This study is conducted in collaboration with the FDA's Center for Tobacco Products and the National Institute on Drug Abuse Research, began in 2011, and commenced the first round of data collection in 2013.
The primary goal of this study is to help scientists understand the ways and reasons people start smoking, quit smoking, and then start again after quitting by tracking research subjects over the long term. It also aims to investigate the effects of different tobacco products on health, such as cardiovascular and respiratory health. Additionally, the research results may serve as a reference for the FDA to develop actions related to tobacco products, ultimately helping to achieve the goals set out in the Family Smoking Prevention and Tobacco Control Act.
According to the FDA website, researchers can now apply to access these restricted use biological marker data files (BRUF). In addition, the first round of data files has been updated to include samples from adults who have previously experimented with or used any tobacco products. The main linked files for restricted and public use have also been updated to reflect the new files and the current availability of samples in the biological sample acquisition program.
The following is the web address for the seventh wave of biomarker data files on the FDA website:
The provided link leads to the summary of a study available on the ICPSR website.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
